EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial
Results of a phase 1 trial of the antibody−toxin conjugate D2C7-ATC targeting EGFR/EGFRvIII in patients with recurrent malignant glioma show encouraging safety and efficacy signals, with translational analyses of patient samples indicating intratumoral and systemic immune activation.